1
|
De Abreu Lourenço R, Devlin N, Howard K, Ong JJ, Ratcliffe J, Watson J, Willing E, Huynh E. Giving a Voice to Marginalised Groups for Health Care Decision Making. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH 2020; 14:5-10. [DOI: 10.1007/s40271-020-00456-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 09/08/2020] [Indexed: 12/16/2022]
|
2
|
Kraus CN, Chapman LW, Korta DZ, Zachary CB. Quality of life outcomes associated with treatment of human immunodeficiency virus (HIV) facial lipoatrophy. Int J Dermatol 2016; 55:1311-1320. [PMID: 27496689 DOI: 10.1111/ijd.13374] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 03/17/2016] [Accepted: 05/11/2016] [Indexed: 11/27/2022]
Abstract
Facial lipoatrophy (FLA), characterized by a decrease in facial volume, has a high prevalence in patients with human immunodeficiency virus (HIV) infection treated with long-term highly active antiretroviral therapy (HAART). The social stigmatization that results from such changes in facial appearance has led some HIV patients to discontinue HAART. The use of fillers is one method of restoring facial volume. A critical outcome of treatment concerns the patient's quality of life (QoL). Although many studies have assessed patient satisfaction, as well as the social and psychological outcomes associated with the correction of HIV FLA, fewer studies have assessed QoL. We reviewed treatment options for HIV FLA with a specific focus on QoL outcomes. Our analysis revealed that the following treatments were associated with improvements in QoL: poly-l-lactic acid; calcium hydroxylapatite; hyaluronic acid; polyacrylamide gel; polyalkylamide gel; polymethylmethacrylate; silicone oil; and autologous fat transfer. The treatment of HIV FLA with these agents appears to improve QoL as assessed by various QoL instruments. Additional studies are required to identify a unifying QoL instrument to effectively assess longitudinal QoL outcomes and to compare treatment modalities.
Collapse
Affiliation(s)
| | - Lance W Chapman
- Department of Dermatology, University of California Irvine, Irvine, CA, USA.
| | - Dorota Z Korta
- Department of Dermatology, University of California Irvine, Irvine, CA, USA
| | | |
Collapse
|
3
|
Objective Analysis of Poly-L-Lactic Acid Injection Efficacy in Different Settings. Dermatol Surg 2015; 41 Suppl 1:S314-20. [DOI: 10.1097/dss.0000000000000552] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Jagdeo J, Ho D, Lo A, Carruthers A. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA). J Am Acad Dermatol 2015; 73:1040-54.e14. [PMID: 26481056 DOI: 10.1016/j.jaad.2015.08.040] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Revised: 08/17/2015] [Accepted: 08/19/2015] [Indexed: 01/07/2023]
Abstract
HIV facial lipoatrophy (FLA) is characterized by facial volume loss. HIV FLA affects the facial contours of the cheeks, temples, and orbits, and is associated with social stigma. Although new highly active antiretroviral therapy medications are associated with less severe FLA, the prevalence of HIV FLA among treated individuals exceeds 50%. The goal of our systematic review is to examine published clinical studies involving the use of filler agents for aesthetic treatment of HIV FLA and to provide evidence-based recommendations based on published efficacy and safety data. A systematic review of the published literature was performed on July 1, 2015, on filler agents for aesthetic treatment of HIV FLA. Based on published studies, poly-L-lactic acid is the only filler agent with grade of recommendation: B. Other reviewed filler agents received grade of recommendation: C or D. Poly-L-lactic acid may be best for treatment over temples and cheeks, whereas calcium hydroxylapatite, with a Food and Drug Administration indication of subdermal implantation, may be best used deeply over bone for focal enhancement. Additional long-term randomized controlled trials are necessary to elucidate the advantages and disadvantages of fillers that have different biophysical properties, in conjunction with cost-effectiveness analysis, for treatment of HIV FLA.
Collapse
Affiliation(s)
- Jared Jagdeo
- Dermatology Service, Sacramento Department of Veterans Affairs Medical Center, Mather, California; Department of Dermatology, University of California Davis, Sacramento, California; Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, New York.
| | - Derek Ho
- Dermatology Service, Sacramento Department of Veterans Affairs Medical Center, Mather, California
| | - Alex Lo
- College of Medicine, State University of New York Downstate Medical Center, Brooklyn, New York
| | - Alastair Carruthers
- Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
5
|
Negredo E, Puig J, Ornelas A, Echeverría P, Bonjoch A, Estany C, Higueras C, Gonzalez-Mestre V, Clotet B. Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. AIDS Res Hum Retroviruses 2015; 31:817-21. [PMID: 25858612 DOI: 10.1089/aid.2015.0004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Long-term results (>5 years) for synthetic substances used to repair facial lipoatrophy have not been published. We performed a cross-sectional study to evaluate the 10-year safety of polyacrylamide hydrogel (Aquamid) among the 751 patients from our unit who received facial infiltrations at least 10 years ago. Epidemiological and clinical data such as complications and patient satisfaction were collected. We also identified those patients who presented a facial infection at any time after infiltration. A total of 104 patients had received Aquamid at least 10 years ago. Before infiltrations, 24.0%, 41.3%, and 34.7% presented very severe, severe, and moderate facial lipoatrophy, respectively. After a mean (SD) of 10.3 (0.5) years since the infiltrations, 19.2%, 47.7%, and 31.7% of patients reported moderate, mild, and no signs of facial lipoatrophy. The values reported by physicians for the same categories were 1.9%, 10.6%, and 87.5%. Indurations were detected in 6.7% of patients and nodules in 3.8%. Five patients (4.8%) had a local infection. A further 15 patients with a shorter follow-up (less than 10 years) presented local infections (overall incidence considering the 751 patients who received infiltrations of Aquamid, 2.7%); the product had to be withdrawn in three cases. The majority of patients were highly satisfied (74.8%) or satisfied (23.4%) with the cosmetic results; among patients with severe or very severe lipoatrophy at baseline, 31.4% were satisfied and 65.7% were highly satisfied. Infiltrations with polyacrylamide hydrogel (Aquamid) are a safe strategy for the treatment of facial lipoatrophy in the long term. The rate of severe complications was low, and patient satisfaction with the cosmetic results was high. However, facial infections may appear in the long term. Therefore, HIV-infected patients who received synthetic substances should be carefully monitored over time.
Collapse
Affiliation(s)
- Eugenia Negredo
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
- Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain
| | - Jordi Puig
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Arelly Ornelas
- Department of Econometrics, Statistics and Spanish Economy, University of Barcelona, Barcelona, Spain
| | - Patricia Echeverría
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Anna Bonjoch
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Carla Estany
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Carmen Higueras
- Plastic Surgery Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Vicente Gonzalez-Mestre
- Plastic Surgery Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Bonaventura Clotet
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
- Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain
- Irsicaixa Foundation, Germans Trias i Pujol Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
6
|
Carruthers J, Carruthers A. Non-operative facial rejuvenation. Plast Reconstr Surg 2015. [DOI: 10.1002/9781118655412.ch66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
Documento de consenso sobre alteraciones metabólicas y riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana. Enferm Infecc Microbiol Clin 2015; 33:40.e1-40.e16. [DOI: 10.1016/j.eimc.2014.06.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 06/18/2014] [Indexed: 01/20/2023]
|
8
|
Duracinsky M, Leclercq P, Herrmann S, Christen MO, Dolivo M, Goujard C, Chassany O. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis 2014; 14:474. [PMID: 25178390 PMCID: PMC4160543 DOI: 10.1186/1471-2334-14-474] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Accepted: 08/19/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Facial lipoatrophy is a frequently reported condition associated with use of antiretroviral (ARV) drugs. Poly-L-lactic acid (PLLA) acid has been used to correct facial lipoatrophy in people with HIV since 2004 both in Europe and the United States. The objective of this study was to establish, in real life conditions and in a large sample, the safety of PLLA (New Fill®, Valeant US, Sinclair Pharma Paris, France) to correct facial lipoatrophy among HIV-positive patients. METHODS A longitudinal study was conducted between 2005 and 2008 in France. Data from 4,112 treatment courses (n = 4,112 patients) and 15,665 injections sessions (1 to 5 injection sessions per treatment course) were gathered by 200 physicians trained in the use of PLLA. RESULTS The average age of patients (88.3% males) treated for lipoatrophy was 47.1 ± 8.1 years (Mean ± SD); 91.2% of patients had been receiving ARV treatment for 10.9 (±4.2) years; CD4 T-cell count was 535 ± 266 cells/mm3. The duration of facial lipoatrophy was 5 ± 2.8 years and the severity was such that 47.3% of patients required five injection sessions of PLLA and 81.9% of the sessions required two vials of the preparation. The final visit, scheduled two months after the last injection session, was attended by 66.0% of patients (n = 2,713). 48 treatment courses (2.8%) were discontinued due to adverse events (AEs). The overall incidence of AEs per course was 18.8%. Immediate AEs, bleeding (3.4%), bruising (2.3%), pain (2.0%), redness at injection site (1.6%), and swelling of the face (0.7%), occurred in 15.4% of courses and 7.0% of sessions (usually during the first session). Non-immediate AEs, mainly nodules (5.7%), inflammation (0.7%), granuloma (0.3%), discolouration (0.2%), and skin hypertrophy (0.1%), occurred in 6.7% of courses. Non-immediate AEs occurred within a time ranging from 21 days (inflammation) to 101 days (granuloma) and all but three of the 13 cases of granuloma resolved. Product efficacy was rated satisfactory by 95% of the patients and physicians. CONCLUSIONS This study demonstrated, in real-life conditions and on a large sample, that PLLA injections were feasible, efficient, and safe when performed by trained physicians.
Collapse
Affiliation(s)
- Martin Duracinsky
- />Bicêtre Hospital, Internal Medicine and Clinical Immunology, University Paris Diderot, Sorbonne Paris Cité, EA REMES, Patient Reported Outcomes Unit, Paris, & AP-HP, Le Kremlin-Bicêtre Paris, France
| | - Pascale Leclercq
- />Grenoble University hospital, Michallon hospital, Information and Treatment Centres for Human Immunodeficiency, BP 217, 38043, CEDEX 09 Grenoble, France
| | - Susan Herrmann
- />Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia Australia
| | | | - Marc Dolivo
- />Association des Œuvres Sociales du Ministère des Affaires Etrangères, 57 Boulevard des Invalides, 75007 Paris, France
| | - Cécile Goujard
- />Bicêtre Hospital, Internal Medicine and Clinical Immunology, & University Paris Sud, Le Kremlin-Bicêtre Paris, France
| | - Olivier Chassany
- />Department of Clinical Research, University Paris Diderot, Sorbonne Paris Cité, EA REMES, Patient Reported Outcomes Unit & AP-HP, Saint-Louis Hospital, Paris, France
| |
Collapse
|
9
|
Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs 2013; 73:651-72. [PMID: 23591907 PMCID: PMC4448913 DOI: 10.1007/s40265-013-0040-4] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Antiretroviral (ARV) treatment for HIV infection has resulted in significant improvement in immunologic and virologic parameters, as well as a reduction in AIDS-defining illnesses and death. Over 25 medications are approved for use, usually in combination regimens of three or four ARVs. Several ARVs are now available as combinatorial products, which have been associated with better adherence. However, while ARV therapy has prolonged life, ARVs also pose a challenge for quality of life as they can cause significant side effects in addition to the potential for drug toxicity and interaction. Given the many complications, side effects and symptoms of HIV/AIDS in addition to associated medical and psychiatric co-morbidities, the need to understand and assess how these interactions may affect health-related quality of life (HRQOL) has grown. Numerous instruments (some validated, others not) are available and have been applied to understanding how ARV treatment affects HRQOL in those with HIV infection, both in clinical trials and clinical practice. In general, ARV treatment improves HRQOL, but this is dependent on the population being studied, the HRQOL instrument being used and the timeframe during which HRQOL has been studied. This article provides a review of the literature on quality of-life assessment as it relates to ARV treatment in developed countries and briefly reviews the HRQOL instruments used, how they have been applied to ARV utilization, and where future research should be applied in HRQOL assessment and HIV infection.
Collapse
Affiliation(s)
- Harleen Gakhar
- Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Amanda Kamali
- Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Mark Holodniy
- Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA. VA Palo Alto Health Care System, 3801 Miranda Ave. (132), Palo Alto, CA 94304, USA
| |
Collapse
|
10
|
Bartus C, Hanke WC, Daro-Kaftan E. A Decade of Experience with Injectable Poly-L-Lactic Acid: A Focus on Safety. Dermatol Surg 2013; 39:698-705. [DOI: 10.1111/dsu.12128] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use. BMC Infect Dis 2013; 13:92. [PMID: 23425246 PMCID: PMC3598243 DOI: 10.1186/1471-2334-13-92] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Accepted: 02/06/2013] [Indexed: 11/10/2022] Open
Abstract
Background Many HIV patients receiving antiretroviral treatment develop lipodystrophy. NEW-FILL® is a polylactic acid injected to treat facial lipoatrophy. The objectives of this study were to describe (1) change in quality of life (QoL) of HIV patients treated with NEW-FILL® in the management of facial lipoatrophy; (2) efficacy of NEW-FILL® using facial photographs and (3) a patient-reported “Overall Treatment Effect” (OTE) scale; and (4) safety of NEW-FILL®. Methods Doctors from 13 treatment centres recruited 230 HIV patients to receive up to 5 sessions of NEW-FILL® injections. Patients self-reported QoL with the ABCD questionnaire before the first set of injections, at 2 months and at 12 to 18 months after the last session of injections. Efficacy was evaluated at each interval through photographs and OTE scale. Safety was evaluated via Case Report Form (CRF) data. Results 64.4% of patients reported QoL improvements of >10% at 2 months, and 58.8% at 12–18 months. Lipoatrophy grades improved at each visit (“no lipoatrophy” or “limited lipoatrophy”: 20.3% at inclusion, 77.4% at 2 months, 58.4% at 12–18 months). Average OTE scores of 5.3 and 5.0 at 2 and 12–18 months indicated “moderate improvement”. Minimum Important Difference (MID) in QoL score was 7.1 points at 2 months; 7.4 points at 12–18 months. For 911 injection sessions performed, 3.4% resulted in “immediate” adverse events, 7% in “non-immediate” events, and 1.7% in “other” events. Conclusions Improvements to quality of life and diminished lipoatrophy visibility were observed in the months immediately following NEW-FILL® treatment and were maintained 12–18 months post-treatment. Most adverse events were mild and transient. ABCD MID thresholds provide clinicians with means to assess the impact of lipoatrophy therapies on QoL.
Collapse
|
12
|
Mole B, Gillaizeau F, Carbonnel E, Pierre I, Brazille P, Grataloup C, Mercier S, Duracinsky M, Weiss L, Piketty C. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study. AIDS Res Hum Retroviruses 2012; 28:251-8. [PMID: 21801082 DOI: 10.1089/aid.2011.0042] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Combination antiretroviral therapy (cART) can cause potentially stigmatizing facial lipoatrophy. Encouraging preliminary results have been reported with 2.5% polyacrylamide hydrogel for facial reconstruction. The aim of this multicenter, open-label noncomparative pilot study was to evaluate the efficacy and safety of intradermal facial injections of polyacrylamide hydrogel in HIV-infected patients with severe facial lipoatrophy. The patients received between two and six injections every 4 weeks, according to the aesthetic results. Clinical efficacy was evaluated by means of facial ultrasonography and photography at baseline and months 6, 12, and 24. Adverse events, patient satisfaction, and quality of life were also assessed. One hundred and eleven patients were enrolled and received at least one injection. Mean cheek skin thickness was 9.7 mm [95% CI: 9.1 to 10.2] at baseline. It rose by an average of 4.4 mm [95% CI: 3.9 to 4.9; p<0.001] at month 12 and a further 0.87 mm [95% CI: 0.52 to 1.23; p<0.001] at month 24. The Overall Treatment Satisfaction scale showed an improvement in more than 88% of patients at all visits, based on the appreciations of the patients, their close relatives and physicians, and on independent assessment of facial photographs. Quality of life improved significantly over time, as shown by the lipodystrophy-specific ABCD scale. No severe adverse effects related to the polyacrylamide hydrogel were noted. Polyacrylamide hydrogel injections were well tolerated and significantly improved the aesthetic aspect and quality of life of HIV-infected patients with facial lipoatrophy.
Collapse
Affiliation(s)
- Bernard Mole
- APHP, Service d'Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, France
| | - Florence Gillaizeau
- APHP, Hôpital Européen Georges Pompidou, Unité d'Epidémiologie et de Recherche Clinique, Paris, France
- INSERM, Centre d'Investigation Epidémiologique 4, Paris, France
| | | | - Isabelle Pierre
- APHP, Service d'Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, France
| | - Patricia Brazille
- Service des Maladies Infectieuses, Hôpital de St-Germain-en-Laye, St-Germain-en-Laye, France
| | - Christine Grataloup
- APHP, Service de Radiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Sylvie Mercier
- Service de Radiologie, Hôpital Edouard Herriot, Lyon, France
| | - Martin Duracinsky
- APHP, Service de Médecine Interne, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Laurence Weiss
- APHP, Service d'Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, France
| | - Christophe Piketty
- APHP, Service d'Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, France
| |
Collapse
|
13
|
Warde M, Gragnani A, Gomes H, Hochman B, Ferreira LM. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires. Int J STD AIDS 2012; 22:596-9. [PMID: 21998182 DOI: 10.1258/ijsa.2009.009086] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Life-expectancy increased in patients infected with HIV/AIDS with the advent of highly active antiretroviral therapy (ART). Facial lipoatrophy is a common complication in these patients, eventually leading to stigma, segregation and a negative impact in quality of life (QOL). We measured the impact of the treatment of facial lipoatrophy with polymethyl methacrylate (PMMA) in the QOL of patients with HIV/AIDS by using four questionnaires that address QOL. Forty consecutive patients on ART referred for facial lipoatrophy treatment were enrolled in this study. The first 20 were allocated to the intervention group and were treated with tissue augmentation with PMMA. The other 20 were allocated to the control group, which received treatment only after six months. At baseline, four questionnaires were applied to all patients in both groups and again after six months. The variation in scores within the control group for all domains of all four instruments was significantly better when compared with that within the control group. We detected improvement in the QOL of patients with HIV/AIDS and facial lipoatrophy when they were treated with PMMA.
Collapse
Affiliation(s)
- M Warde
- Division of Plastic Surgery, Federal University of Sao Paulo, São Paulo, Brazil
| | | | | | | | | |
Collapse
|
14
|
Gagnon M. Understanding the experience of reconstructive treatments from the perspective of people who suffer from facial lipoatrophy: a qualitative study. Int J Nurs Stud 2011; 49:539-48. [PMID: 22130507 DOI: 10.1016/j.ijnurstu.2011.11.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Revised: 10/02/2011] [Accepted: 11/01/2011] [Indexed: 10/14/2022]
Abstract
BACKGROUND Facial lipoatrophy has been described as the most distressing and stigmatizing expression of the lipodystrophy syndrome, a syndrome that is caused by antiretroviral combination therapy. In recent years, reconstructive treatments (such as poly-l-lactic acid and polyalkylimide) have been increasingly considered for this condition. These treatments allow for facial contours and facial fullness to be restored while being minimally invasive. OBJECTIVE The main objective of this qualitative research was to explore and describe the experience of people who suffer from facial lipoatrophy, specifically in regard to reconstructive treatments. METHOD A qualitative design, which incorporates explorative and descriptive attributes, was thought to be an appropriate choice for this research project. The data was collected using semi-structured interviews and was then analyzed following the principles of thematic analysis. PARTICIPANTS Over a period of three months, 11 men and 1 woman enrolled in the study which was conducted in Montreal (Quebec), Canada. FINDINGS Overall, participants explained that facial lipoatrophy had forced them into a situation of intense vulnerability by making them recognizable as persons living with HIV/AIDS and discreditable in the eyes of others. In this sense, they were willing to go to great lengths to restore their facial features and regain a sense of normalcy. Findings revealed that people who suffer from facial lipoatrophy engage in a process of reconstruction to reduce the visibility and disruptiveness of their condition but face many uncertainties along the way. CONCLUSIONS While the findings of this research corroborated what has been previously stated by other researchers about the impact of reconstructive treatments, they also shed light on the consequences of not making these treatments accessible as well as the undocumented realities of those who cannot afford the recommended course of dermal fillers.
Collapse
Affiliation(s)
- Marilou Gagnon
- University of Ottawa, Faculty of Health Sciences, School of Nursing, 451 Smyth Road, Ottawa, Ontario, Canada K1H 8M5.
| |
Collapse
|
15
|
Rauso R, Freda N, Parlato V, Gherardini G, Amore R, Tartaro G. Polyacrylamide Gel Injection for Treatment of Human Immunodeficiency Virus-Associated Facial Lipoatrophy: 18 Months Follow-Up. Dermatol Surg 2011; 37:1584-9. [DOI: 10.1111/j.1524-4725.2011.02131.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Soares FMG, Costa IMC. Lipoatrofia facial associada ao HIV/AIDS: do advento aosconhecimentos atuais. An Bras Dermatol 2011; 86:843-62; quiz 863-4. [DOI: 10.1590/s0365-05962011000500001] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2010] [Accepted: 11/28/2010] [Indexed: 02/06/2023] Open
Abstract
O advento da AIDS trouxe novos desafios para a Dermatologia. A terapia antirretroviral mudou drasticamente a morbimortalidade associada à infecção pelo HIV/AIDS, mas contribuiu para o surgimento de outras novas situações que exigem abordagem adequada do dermatologista. A Síndrome Lipodistrófica Associada ao HIV/AIDS tem origem multifatorial, mas está fortemente associada ao uso dos antirretrovirais. Compreende alterações na distribuição da gordura corporal, acompanhada ou não de alterações metabólicas. A perda da gordura da face, chamada lipoatrofia facial, é dos sinais mais estigmatizantes da síndrome. Esta condição, muitas vezes reveladora da doença, trouxe de volta o estigma da AIDS. É necessário que os especialistas que atuam com pacientes com HIV/AIDS identifiquem estas alterações e busquem opções de tratamento, dentre as quais se destaca o implante com polimetilmetacrilato, que é disponibilizado para tratamento da lipoatrofia facial associada ao HIV/AIDS no Sistema Único de Saúde
Collapse
|
17
|
Abstract
Morphologic and metabolic abnormalities, including subcutaneous adipose tissue wasting, central adipose tissue accumulation, dyslipidemia and disorders of glucose metabolism are common among HIV-infected patients receiving highly active antiretroviral therapy (HAART) and contribute to the risk of cardiovascular disease in this population. The pathogenesis of these disorders is due to complicated interactions between effects of chronic HIV infection, HAART medications and patient factors, including genetic susceptibility. HAART has transformed HIV into a chronic condition for many patients and as a result the majority of HIV-infected patients in many areas of the developed world will soon be aged ≥50 years. Given that metabolic and cardiovascular diseases increase with aging, knowledge of the optimal management of these conditions is essential for practitioners caring for HIV-infected patients, including endocrine subspecialists. This Review highlights the clinical management of these disorders, focusing on the latest evidence regarding the efficacy of treatment strategies, newly available medications and potential interactions between HAART medications and medications used to treat metabolic disorders.
Collapse
Affiliation(s)
- Todd T Brown
- Division of Endocrinology and Metabolism, Johns Hopkins University, 1830 East Monument Street, Baltimore, MD 21287, USA.
| | | |
Collapse
|
18
|
NICHOLS BENJAMINJ, CARPENTER JANETTE, HRIBAR KAMBRIDGEP, GO JOHN, RICE DALEH. Acute Parotitis after Injection of Poly-L-Lactic Acid for Malar Augmentation: A Case Report and Review of Relevant Anatomy. Dermatol Surg 2011; 37:381-6. [DOI: 10.1111/j.1524-4725.2011.01892.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
|
20
|
Bonnet E. New and emerging agents in the management of lipodystrophy in HIV-infected patients. HIV AIDS (Auckl) 2010; 2:167-78. [PMID: 22096395 PMCID: PMC3218685 DOI: 10.2147/hiv.s13429] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Lipodystrophy remains a major long-term complication in human immunodeficiency virus-infected patients under antiretroviral (ARV) therapy. Patients may present with lipoatrophy or lipohypertrophy or both. The choice of treatments to improve fat redistribution depends on the form of lipodystrophy and its duration. Measures known to improve lipoatrophy are switches in ARV therapy (stavudine or zidovudine to abacavir or tenofovir) and filling interventions. Pioglitazone may be added to these measures, although any benefits appear small. Uridine and leptin were found to be disappointing so far. Regarding lipohypertrophy, diet and exercise, recombinant human growth hormone, and metformin may reduce visceral fat, but may worsen subcutaneous lipoatrophy. Surgical therapy may be required. Attractive pharmacologic treatments include growth hormone-releasing factor and leptin. Adiponectin and adiponectin receptors are promising therapeutic targets to explore.
Collapse
Affiliation(s)
- Eric Bonnet
- Service des Maladies Infectieuses, Hôpital Purpan, Toulouse, France
| |
Collapse
|
21
|
Ross JJ, Malhotra R. Orbitofacial rejuvenation of temple hollowing with Perlane injectable filler. Aesthet Surg J 2010; 30:428-33. [PMID: 20601570 DOI: 10.1177/1090820x10374099] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Temple hollowing with soft tissue volume loss is well recognized in HIV lipoatrophy. Similar changes occur as part of aging, with skeletalization of the orbital rim and clipping of the eyebrow tail. OBJECTIVES The authors report their initial experience treating temple volume loss and orbitofacial asymmetry with nonanimal stabilized hyaluronic acid (NASHA). METHODS This study was a retrospective, interventional case series with a patient satisfaction questionnaire and independent physician grading of results. Patients initially received approximately 1 mL of Perlane (Q-Med, Uppsala, Sweden; Medicis, Inc., Scottsdale, Arizona) injected into the superficial fascia of each temple. The filler was placed behind the frontozygomatic process to soften the bony contour of the lateral orbital rim. Outcome measures included satisfaction with injection procedure, fulfillment of expectations, satisfaction with appearance, change in self-confidence, the need for retreatment, and complications. RESULTS Twenty patients were treated, for a total of 39 temples. Mean follow-up was nine months (range, four to 14 months). Patients were primarily female (90%), all were Caucasian, and their ages ranged from 20 to 60 years. Eighteen patients had age-related temple hollowing, one had dysthyroid volume loss, and one had hollowing due to orbitotemporal neurofibromatosis. The majority had 1-mL injections to each side (range, 0.3-3 mL). One patient received 3 mL to correct asymmetry. The procedure was well tolerated with ice pack cooling and no local anesthesia. Of 16 patients who replied to the questionnaire, 13 were very or moderately satisfied and requested repeat treatment, whereas three were only mildly satisfied or ambivalent. Side effects included transient mild or moderate discomfort, superficial vein prominence, and localized bruising. CONCLUSIONS This series suggests the effective and safe application of Perlane in temple hollow rejuvenation and correction of asymmetry. It offers tolerability, high patient satisfaction, few complications, and the option of reversibility.
Collapse
Affiliation(s)
- Jonathan J Ross
- Corneo Plastic Unit, Queen Victoria Hospital, Holtye Road, East Grinstead, United Kingdom
| | | |
Collapse
|
22
|
Calmy A, Bloch M, Wand H, Delhumeau C, Finlayson R, Rafferty M, Norris R, Hirschel B, Cooper DA, Carr A. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010; 11:493-501. [PMID: 20236365 DOI: 10.1111/j.1468-1293.2009.00817.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Lipoatrophy can complicate thymidine analogue nucleoside reverse transcriptase inhibitor (tNRTI)-based antiretroviral therapy (ART). Lipoatrophy may be less likely with ART including ritonavir-boosted lopinavir (LPV/r). Small, placebo-controlled studies found that uridine (in tNRTI recipients) and pravastatin improved HIV lipoatrophy over 12 weeks. Today, most patients with lipoatrophy receive non-tNRTI-based ART; the effect of uridine in such patients is unknown. METHODS We performed a prospective, randomized trial in lipoatrophic adults with plasma HIV RNA<50 HIV-1 RNA copies/mL on tNRTI-sparing ART including LPV/r. Patients received uridine [36 g three times a day (tid) on 10 consecutive days per month; n=10], pravastatin [40 mg every night (nocte); n=12], uridine plus pravastatin (n=11) or neither (n=12) for 24 weeks. The primary endpoint was mean change in limb fat mass as assessed by dual-energy X-ray absorptiometry (DEXA). With 20 patients per intervention, the study had 80% power to detect a mean difference between a treatment and the control of 0.5 kg, assuming a standard deviation of 0.9 and an alpha threshold equal to 5% (two-sided). RESULTS Of 45 participants (all men, with median age 49.5 years and median limb fat 2.6 kg), two discontinued pravastatin and one participant stopped both pravastatin and uridine. The difference between the mean changes in limb fat mass for uridine vs. no uridine was 0.03 kg [95% confidence interval (CI) -0.35, +0.28; P=0.79]. The respective difference for pravastatin was -0.03 kg (95% CI -0.29, +0.34; P=0.84). Pravastatin slightly decreased total cholesterol (0.44 mmol/L; P=0.099). Visceral adipose tissue measured by computed tomography did not change significantly. CONCLUSION In this population and at the doses used, neither uridine nor pravastatin for 24 weeks significantly increased limb fat mass.
Collapse
Affiliation(s)
- A Calmy
- HIV, Immunology and Infectious Diseases Unit, Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Non-surgical Volume Enhancement with Fillers in the Orbit and Periorbital Tissues: Cosmetic and Functional Considerations. ACTA ACUST UNITED AC 2010. [DOI: 10.1007/978-3-540-85542-2_15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
24
|
Innes S, Levin L, Cotton M. LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART. South Afr J HIV Med 2009; 10:76-80. [PMID: 20706598 DOI: 10.4102/sajhivmed.v10i4.264] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
Lipodystrophy syndrome (LD) is common in HIV-infected children, particularly those taking didanosine, stavudine or zidovudine. Lipo-atrophy in particular causes major stigmatisation and interferes with adherence. In addition, LD may have significant long-term health consequences, particularly cardiovascular. Since the stigmatising fat distribution changes of LD are largely permanent, the focus of management remains on early detection and arresting progression. Practical guidelines for surveillance and avoidance of LD in routine clinical practice are presented. The diagnosis of LD is described and therapeutic options are reviewed. The most important therapeutic intervention is to switch the most likely offending antiretroviral to a non-LD-inducing agent as soon as LD is recognised. Typically, when lipoatrophy or lipohypertrophy is diagnosed the thymidine nucleoside reverse transcriptase inhibitor (NRTI) is switched to a non-thymidine agent such as abacavir (or tenofovir in adults). Where dyslipidaemia is predominant, a dietician review is helpful, and the clinician may consider switching to a protease inhibitor-sparing regimen or to atazanavir.
Collapse
Affiliation(s)
- Steve Innes
- KID-CRU (Children's Infectious Diseases Clinical Research Unit), Tygerberg Children's Hospital and Stellenbosch University, Tygerberg, W Cape
| | | | | |
Collapse
|
25
|
Rocchio TM. Augmentation of atrophic plantar soft tissue with an acellular dermal allograft: a series review. Clin Podiatr Med Surg 2009; 26:545-57. [PMID: 19778688 DOI: 10.1016/j.cpm.2009.07.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Treatment of plantar fat pad migration and atrophy has caused concern for decades. Patients can present with pain, callus formation, or ulceration. The purpose of this article is to review the results of a consecutive series of patients treated for fat pad atrophy of the plantar foot, using a minimally invasive implantation of an acellular human dermal allograft as a tissue augmentation. This material was chosen for the fat pad supplementation because of previous reports of success in tendon and ligament augmentation, wound healing, and interpositional arthroplasty.
Collapse
|
26
|
Sturm LP, Cooter RD, Mutimer KL, Graham JC, Maddern GJ. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care STDS 2009; 23:699-714. [PMID: 19673594 DOI: 10.1089/apc.2008.0230] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The objective of this study was to assess the safety and efficacy of injectable semipermanent and permanent dermal fillers, compared to other facial augmentation techniques, for the management of facial lipoatrophy as a result of highly active antiretroviral therapy (HAART) for HIV infection through a systematic review of the literature. A systematic search strategy was used to retrieve relevant studies. Inclusion of articles was by the application of a predetermined protocol, independent assessment by two reviewers, and a final consensus decision. One randomized controlled trial (RCT), one pseudo-RCT, two nonrandomized comparative studies, and seven case series were included for review. Injections with permanent and semipermanent dermal fillers improved subjective ratings of appearance and resulted in high patient satisfaction. Although short-term safety appeared favorable, of the seven studies that reported lumps, three studies reported these events in more than 40% of patients. Long-term safety data were lacking. Evidence suggests that permanent and semipermanent dermal fillers achieve their objective, which is to decrease the visible effects of HIV-associated facial lipoatrophy, with high patient satisfaction. Safety appears favorable in the short term, but further studies are required to determine long-term outcomes.
Collapse
Affiliation(s)
- Lana P. Sturm
- ASERNIP-S, Royal Australasian College of Surgeons, Adelaide, South Australia
| | - Rodney D. Cooter
- Waverley House Plastic Surgery Centre, Adelaide, South Australia
| | | | - John C. Graham
- Lismore Base Hospital and St Vincents Private Hospital, Lismore, New South Wales, Australia
| | - Guy J. Maddern
- ASERNIP-S, Royal Australasian College of Surgeons, Adelaide, South Australia
- University of Adelaide Discipline of Surgery, Queen Elizabeth Hospital, Adelaide, South Australia
| |
Collapse
|
27
|
|
28
|
Abstract
The spectrum of drugs used in HIV-infected patients has dramatically changed since triple antiretroviral combinations were introduced, albeit at the expense of some severe adverse events, in 1996. Abandonment of stavudine in countries that can afford it, new drugs from new classes with a wide therapeutic window and the impressive scale-up of drug access in resource-limited settings are several of the key new events. Drug safety is likely to be the most important factor to distinguish one antiretroviral regimen from another. We review life-threatening adverse events, adverse events of new investigational or recently marketed drugs, adverse events with a genetic component and tissue-specific adverse events of fat, heart, bone, kidney and liver.
Collapse
|
29
|
Negredo E, Puig J, Aldea D, Medina M, Estany C, Pérez-Álvarez N, Rodríguez-Fumaz C, Muñoz-Moreno JA, Higueras C, Gonzalez-Mestre V, Clotet B. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009; 25:451-5. [PMID: 19320569 DOI: 10.1089/aid.2008.0230] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Infiltrations with synthetic substances are effective strategies for repairing facial lipoatrophy. However, few data are available on long-term safety. We describe the safety of polyacrylamide hydrogel in 145 patients who received facial infiltrations with Aquamid from September 2002 to April 2004. Epidemiological, clinical (mainly complications), and psychological data (patient satisfaction) were collected. We also recorded all patients who presented with a local infection at any time after receiving an infiltration. Sixty-two percent of patients presented with severe facial lipoatrophy before infiltration. The cumulative volume of Aquamid injected was 5.5 ml (4-18) per patient. During a mean (SD) of 50.2 (4.3) months after infiltration, only one patient presented with a local infection. Small palpable, nonvisible nodules or indurations were the most frequent complications (19.3% and 6.2%, respectively). If we include the remaining patients from our center (n = 294) who also received Aquamid (although less than 4 years ago), a further three patients presented with a local infection (incidence of 0.9%). Most patients (88.9%) were "satisfied" or "very satisfied" with the results; patients with mild to moderate baseline facial lipoatrophy were more satisfied than those with severe lipoatrophy ("very satisfied": 92.7% versus 86.5%, respectively). Only 17.4% reported mild impairment of lipoatrophy and only 9.2% required new infiltrations; however, 76% would have preferred more infiltrations. The high patient satisfaction and the low number of severe complications after at least 4 years of facial infiltrations with Aquamid reflect the long-term safety of this product for the repair of facial lipoatrophy. However, prolonged follow-up of these patients is recommended to detect unexpected long-term adverse reactions.
Collapse
Affiliation(s)
- Eugenia Negredo
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Jordi Puig
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - David Aldea
- Plastic Surgery Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Manuel Medina
- Plastic Surgery Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Carla Estany
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Núria Pérez-Álvarez
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
- Statistics and Operations Research Department, Technical University of Catalonia, Barcelona, Spain
| | - Carmina Rodríguez-Fumaz
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Jose A. Muñoz-Moreno
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Carmen Higueras
- Plastic Surgery Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Vicente Gonzalez-Mestre
- Plastic Surgery Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Bonaventura Clotet
- Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
- Irsicaixa Foundation, Germans Trias i Pujol Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
30
|
Benn P, Sauret-Jackson V, Cartledge J, Ruff C, Sabin CA, Moyle G, Linney A, Reilly G, Edwards SG. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. HIV Med 2009; 10:351-5. [PMID: 19490181 DOI: 10.1111/j.1468-1293.2009.00694.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Thymidine nucleoside reverse transcriptase inhibitors (NRTIs) are associated with subcutaneous fat loss. Facial changes cannot be assessed by dual-energy X-ray absorptiometry (DEXA) scans. There are limited objective data on the reversibility of facial lipoatrophy. METHODS We performed a facial volume substudy of a randomized thymidine NRTI replacement study carried out in HIV-infected subjects with moderate to severe lipoatrophy. Facial volume changes were assessed using validated 3D laser imaging. Changes in body composition were measured using DEXA scans. The association between changes in facial volume and body composition parameters at 48 weeks was measured using Spearman's rank correlation. RESULTS Forty-seven individuals (46 male), 11 receiving zidovudine and 36 receiving stavudine, switched to either tenofovir disoproxil fumarate (DF) (n=23) or abacavir (ABC) (n=24). Thirty-nine of these 47 patients (84.8%) reported facial lipoatrophy at baseline. The median volume increase in both cheeks from baseline was 1857.3 mm(3). These volume changes and increases in limb fat at 48 weeks were similar in the two groups and correlated significantly (Spearman's r=0.41, P=0.004). CONCLUSIONS Facial volume in lipoatrophic individuals was found to increase after thymidine NRTI replacement. We demonstrated a significant correlation between improvements in facial and limb fat parameters. Switching from thymidine NRTIs in patients with facial lipoatrophy could potentially reduce the need for cosmetic interventions.
Collapse
Affiliation(s)
- P Benn
- Department of Genitourinary Medicine, Mortimer Market Centre, Camden PCT, Off Capper Street, London WC1E 6JB, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Carey D, Baker D, Petoumenos K, Chuah J, Rogers GD, Watson J, Cooper DA, Emery S, Carr A. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. HIV Med 2009; 10:163-72. [DOI: 10.1111/j.1468-1293.2008.00667.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab 2008; 93:2937-45. [PMID: 18685115 PMCID: PMC2515075 DOI: 10.1210/jc.2008-1019] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2008] [Accepted: 06/23/2008] [Indexed: 01/16/2023]
Abstract
Subcutaneous atrophy and central fat accumulation are common among HIV-infected patients receiving highly active antiretroviral therapy, and may be accompanied by dyslipidemia and insulin resistance. These fat changes, although commonly referred to together as lipodystrophy, are best considered as separate disorders, with distinct pathogeneses and treatment approaches. These morphological and metabolic abnormalities first appeared after introduction of protease inhibitors more than 10 yr ago, but research has demonstrated that their pathogenesis is multifactorial, with contributions from other antiretroviral medications, patient-related factors, and HIV itself. Switching to a less toxic highly active antiretroviral therapy regimen has shown partial effectiveness for the management of fat atrophy and lipid abnormalities. Lifestyle modification or surgical approaches are the treatment of choice for lipohypertrophy, although novel therapies targeting the GH axis show promise. HIV-related dyslipidemia may be difficult to treat, and can be complicated by drug-drug interactions between some lipid-lowering medications and antiretroviral medications. Treatment of diabetes in HIV-infected patients should generally follow established guidelines, but thiazolidinediones, rather than metformin, may be considered first-line treatment in a patient with lipoatrophy, given their potential to increase sc fat. The contribution of body fat changes and metabolic abnormalities to cardiovascular risk and the changing risk profiles of newer antiretroviral regimens are under intense investigation.
Collapse
Affiliation(s)
- Todd T Brown
- Division of Endocrinology and Metabolism, Johns Hopkins University, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA.
| |
Collapse
|